Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA to create inter-center ad group

Executive Summary

FDA is forming an inter-center group to oversee advertising policies for different products regulated by FDA, Acting Commissioner Lester Crawford, PhD, announces Aug. 2 at a National Press Club luncheon in Washington, D.C. FDA will issue guidance on outdoor advertising, comparative claims and implied claims later this year, he adds. The agency released three draft guidances related to direct-to-consumer advertising in February (1"The Pink Sheet" Feb. 9, 2004, p. 3)...

You may also be interested in...



FDA To Create Inter-Center Advertising Policy Group

FDA is forming an inter-center group to oversee advertising policies for different products regulated by the agency, Acting Commissioner Lester Crawford announced at a recent National Press Club luncheon in Washington, D.C

FDA Releases DTC Guidances; “Not The Last Word” On Ads, McClellan Says

FDA's publication of three draft guidances on direct-to-consumer advertising is unlikely to relieve pressure on the agency to explain its approach to enforcement actions against drug manufacturers that repeatedly run false and misleading promotions

Sanofi Alliance Is Big Boost For Company Behind Type 1 Diabetes Prevention Drug

Sanofi has deprioritized its presence in type 1 diabetes in recent years but could help turn teplizumab into a game-changer blockbuster product.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS044466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel